Understanding the complex landscape of bioconjugates

Bioconjugates are a rapidly expanding therapeutic modality demonstrating tremendous benefit for cancer patients already, and with significant promise in inflammatory, infectious and rare diseases. Key to the successful development of bioconjugates is the selection of an appropriate conjugation strategy.

In this eBook, Dr. Nicolas Camper, Vice President, and Dr. Petra Dieterich, Senior Vice President & Scientific Leader, Abzena, review and discuss the main categories of therapeutic bioconjugates, focusing on their key required characteristics or target product profile (TPP). Including, key considerations for selecting the most appropriate conjugation strategy for each application and insights into technological options along with real-world examples of bioconjugates in clinical development and in-market.